10x Genomics (NASDAQ:TXG) stock slid 14% Wednesday amid news that Illumina (ILMN) has acquired single cell analysis technology company Fluent BioSciences and a downgrade by Deutsche Bank.

Single-cell transcriptomics has revolutionized the ... particularly in droplet-based methods such as Drop-seq and 10x Chromium—frequently lead to inaccurate results, causing researchers to ...

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

Oxford Nanopore Technologies announced its expanded collaboration with 10x Genomics, Inc. to enable seamless compatibility between their latest technologies, bringing more accurate, cost-effective and ...

In 2024, 10x Genomics worked to cement its status as “the single-cell analysis company,” making upgrades and additions to its portfolio of tools used by researchers in academia and industry to ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

The high level of single-cell resolution leads to groundbreaking insights across applications, including gene and protein expression investigation, immune phenotyping, CRISPR perturbation analysis, ...

The Single-Cell Analytics Innovation Lab (SAIL ... into an easy-to-use package to perform and develop droplet microfluidics experiment. Xenium by 10X Genomics In Situ platform enables subcellular ...

We offer a range of services, including single cell RNA sequencing and spatial transcriptomics. Our facility is equipped with state-of-art instruments, including the 10X Genomics Chromium X which ...

"This development further validates the strength of our broad patent portfolio, which helps protect and preserve the world-class innovation engine at 10x," said Eric S. Whitaker, Chief Legal ...